F.C. Barone
Department of Cardiovascular Pharmacology
SmithKline Beecham Pharmaceuticals
UW2521
King of Prussia
USA
Name/email consistency: high
- SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. Barone, F.C., Irving, E.A., Ray, A.M., Lee, J.C., Kassis, S., Kumar, S., Badger, A.M., White, R.F., McVey, M.J., Legos, J.J., Erhardt, J.A., Nelson, A.H., Ohlstein, E.H., Hunter, A.J., Ward, K., Smith, B.R., Adams, J.L., Parsons, A.A. J. Pharmacol. Exp. Ther. (2001)
- Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Barone, F.C., Irving, E.A., Ray, A.M., Lee, J.C., Kassis, S., Kumar, S., Badger, A.M., Legos, J.J., Erhardt, J.A., Ohlstein, E.H., Hunter, A.J., Harrison, D.C., Philpott, K., Smith, B.R., Adams, J.L., Parsons, A.A. Med. Res. Rev (2001)
- Therapeutic potential of anti-inflammatory drugs in focal stroke. Barone, F.C., Parsons, A.A. Expert. Opin. Investig. Drugs (2000)
- Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. Barone, F.C., Campbell, W.G., Nelson, A.H., Feuerstein, G.Z. J. Hypertens. (1998)
- Calcium channel blockers in cerebral ischaemia. Barone, F.C., Feuerstein, G.Z., Spera, R.P. Expert. Opin. Investig. Drugs (1997)
